Journal of Biological Chemistry · 2004 · 53 citations · 41 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyApoptosis In CancerApoptosis PharmacologyColorectal CancerCytotoxic ChemotherapyMalignant Neoplasms5-Fluorouracil Therapy5-Fluorouracil TreatmentCancer Cell ApoptosisP53 AbnormalityP53 MutationPolyamine BiosynthesisTranscriptome Analysis
The thymidylate synthase inhibitor 5-fluorouracil (5-FU) is used widely for chemotherapy of colorectal carcinoma. Recent studies showed that 5-FU affects polyamine metabolism in colon carcinoma cells. We therefore examined whether combinations of 5-FU with drugs that specifically target polyamine metabolism, i.e. N1,N11-diethylnorspermine (DENSPM) or alpha-difluoromethylornithine (DFMO), have synergistic effects in killing HCT116 colon carcinoma cells with wild-type or absent p53. Our results showed that simultaneous 5-FU and DENSPM, a spermine analogue, synergistically increased transcript levels of the polyamine catabolism enzyme spermidine/spermine N1-acetyltransferase, depleted spermine and spermidine, increased acetylated spermidine, and produced synergistic tumor cell apoptosis in both p53 wild-type and p53-null variants. By contrast, simultaneous combination of 5-FU with DFMO, an inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, depleted putrescine but did not produce synergistic cell killing. Some pre-treatment and post-treatment regimens of DENSPM and DFMO were antagonistic to 5-FU depending on cellular p53 status. Protein and transcriptome expression analysis showed that combined 5-FU and DENSPM treatment activated caspase 9, but not caspase 3, and significantly suppressed NADH dehydrogenases and cytochrome c oxidases, consistent with the observed increase in hydrogen peroxide, loss of mitochondrial membrane potential, and release of cytochrome c. Our findings demonstrate the importance of the polyamine pathway in 5-FU effects and suggest that the combination of 5-FU with DENSPM has potential for development as therapy for colorectal carcinoma.
41
Requirement for p53 and p21 to Sustain G <sub>2</sub> Arrest After DNA Damage
Fred Bunz, Annie Dutriaux, Christoph Lengauer et al. · Science · 1998 · 2.8K citations
Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo
Razqallah Hakem, Anne Hakem, Gordon S. Duncan et al. · Cell · 1998 · 1.3K citations · Full text
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
Todd Waldman, K. W. Kinzler, Bert Vogelstein · PubMed · 1995 · 1.2K citations
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
F. L. Meyskens, Eugene W. Gerner · PubMed · 1999 · 340 citations · Full text
Medicine, Oncology, Pharmacology +14